US0042251084 - Common Stock
ACADIA PHARMACEUTICALS INC
NASDAQ:ACAD (11/28/2023, 10:12:43 AM)
22.02
-0.1 (-0.45%)
ACADIA Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The company is headquartered in San Diego, California and currently employs 511 full-time employees. The company went IPO on 2004-05-27. Its clinical-stage development are focused on treating the negative symptoms of schizophrenia, Prader-Willi syndrome, Alzheimer's disease psychosis and neuropsychiatric symptoms in central nervous system disorders. Its pipeline includes NUPLAZID, Trofinetide, ACP-204 and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a treatment for Parkinson's Disease Psychosis. Trofinetide is a treatment for Rett Syndrome. Trofinetide is a synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. ACP-204 is a treatment for Alzheimer’s Disease Psychosis. The company also owns rights to NNZ-2591 in both Rett and Fragile X syndrome.
ACADIA PHARMACEUTICALS INC
12830 El Camino Real, Suite 400
San Diego CALIFORNIA 92130
P: 18585582871.0
CEO: Stephen R. Davis
Employees: 511
Website: https://acadia.com/
Many industry heavyweights are on the hunt for fresh new ideas -- great news for biotech stocks to buy with strong pipelines.
Acadia Pharma beats earnings expectations with record revenues from DAYBUE and NUPLAZID, and provides positive outlook for 2023.
Here you can normally see the latest stock twits on ACAD, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: